Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05600231 · ClinicalTrials.gov registry record · Phase 4

A Study of Virtually Supervised Mouth Rinses and Flossing

A Phase 4 study, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).

Completed
Registry status
Phase 4
Development phase
284
Enrollment target

NCT05600231: Completed Phase 4 study, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).

NCT05600231 is a Phase 4 study that has completed, run by Johnson & Johnson Consumer Inc. (J&JCI). The registered enrollment target is 284 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05600231, a Phase 4 study, has completed, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).

COMPLETED
Registry status
Phase 4
Development phase
284 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the efficacy of brushing, flossing, and rinsing with essential oil mouth rinses; brushing and flossing; versus brushing and rinsing with essential oil mouth rinses; and brushing only for the prevention and reduction of plaque and gingivitis.

Primary Outcome

Interproximal Mean TPI after 12 weeks of product use will be reported. Plaque area will be scored by the Turesky Modification of the Quigley-Hein Plaque Index, on 6 surfaces (distobuccal, midbuccal and mesiobuccal, distolingual, midlingual and mesiolingual) of all scorable teeth, following disclosing: 0 (no plaque); 1 (separate flecks or discontinuous band of plaque around the gingival (cervical) margin); 2 (thin, up to 1 millimeter \[mm\]), continuous band of plaque at the gingival margin); 3 (

Interventions

  • OTHER Colgate Cavity Protection Toothpaste
  • OTHER Reach Unflavored Waxed Dental Floss
  • OTHER LISTERINE COOL MINT Antiseptic Mouthwash
  • OTHER LISTERINE COOL MINT ZERO Alcohol Mouthwash

Trial Details

FieldValue
Enrollment Target 284 participants
Start Date 2022-04-18
Est. Completion 2022-07-25
Phase Phase 4

What the finished NCT05600231 record still lists

NCT05600231 is an interventional study that assigns participants to a tested intervention. The registered 284 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (45% lower).

The record links to 0 conditions, and to 4 interventions - of which Colgate Cavity Protection Toothpaste is the first listed.

NCT05600231 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05600231 about?

NCT05600231 is a clinical study titled "A Study of Virtually Supervised Mouth Rinses and Flossing". The purpose of this study is to evaluate the efficacy of brushing, flossing, and rinsing with essential oil mouth rinses; brushing and flossing; versus brushing and rinsing with essential oil mouth rinses; and brushing only for the prevention and reduction of plaque and gingivitis.

What is the current status of trial NCT05600231?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 284 participants. The study started on 2022-04-18. Estimated completion is 2022-07-25.

What interventions are being tested in trial NCT05600231?

The interventions under investigation include: Colgate Cavity Protection Toothpaste (OTHER), Reach Unflavored Waxed Dental Floss (OTHER), LISTERINE COOL MINT Antiseptic Mouthwash (OTHER), LISTERINE COOL MINT ZERO Alcohol Mouthwash (OTHER).

Who is sponsoring clinical trial NCT05600231?

This trial is sponsored by Johnson & Johnson Consumer Inc. (J&JCI), which has 40 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05600231's enrollment target sits among peer trials

284 302nd of 2000 higher than 1,698 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05263206 · 284 participants · Phase 3

    Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

  • NCT05769218 · 284 participants · NA

    PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study

  • NCT06856577 · 284 participants · Phase 3

    Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

  • NCT06963034 · 284 participants · Phase 3

    NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05600231, the US trial registry maintained by the National Library of Medicine. NCT05600231 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.